Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

WHITBY PHARMACEUTICAL ACQUIRES 11 GLAXO PRODUCTS

Executive Summary

WHITBY PHARMACEUTICAL ACQUIRES 11 GLAXO PRODUCTS with aggregate annual sales of $9.5 mil. Whitby announced the purchase Jan. 19. The purchase price was not disclosed. Whitby Pharmaceuticals is the new name (adopted in Sept. 1989) by chemical manufacturer Ethyl Corp's drug marketing business. Ethyl established the drug marketing effort in 1987 as Ethyl Pharmaceutical Inc. Ethyl's finished drug business is made up of Birmingham, Alabama-based Russ Pharmaceuticals (acquired by Ethyl in March, 1989) and the former Nelson Research and Development (acquired in 1987). Nelson has been rechristened Whitby Research. Whitby subsidiary Russ will market the products, which are produced by a contract manufacturer. Russ currently markets a single product line, the Lortab series of hydrocondone-based prescription analgesics. The products involved in the deal are Trinsicon hematinic concentrate, Trinsicon M hematinic modified (without folic acid), vitamin formulations Vicon-C, Vicon Forte, Vicon Plus, and Vi-Zac, the hemorrhoid cream Corticaine (hydrocortisone acetate), asthma treatment Amesec, Ethatab, used in vascular disorders, laxative Athrocholin and antihistamines Histabid and Histabid Duracaps.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS016879

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel